Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 3, 2016
Translation of New Molecular Imaging Approaches to the Clinical Setting: Bridging the Gap to ImplementationSuzanne C van Es, Clasina M Venema, Andor W J M Glaudemans, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 14, 2017
89Zr-Bevacizumab PET: Potential Early Indicator of Everolimus Efficacy in Patients with Metastatic Renal Cell CarcinomaSuzanne C van Es, Adrienne H Brouwers, Shekar V K Mahesh, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2020
Assessment of Bone Lesions with 18F-FDG PET Compared with 99mTc Bone Scintigraphy Leads to Clinically Relevant Differences in Metastatic Breast Cancer ManagementSuzanne C van Es, Ton Velleman, Sjoerd G Elias, et al.Theranostics|September 15, 2018
Comparative biodistribution analysis across four differentFrederike Bensch, Michaël M Smeenk, Suzanne C van Es, et al.The American Journal of Surgical Pathology|July 9, 2019
Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 ResultsSuzanne C van Es, Bert van der Vegt, Frederike Bensch, et al.Molecular Oncology|July 28, 2019
RAS and BRAF mutations in cell-free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue-tested RAS wild-type advanced colorectal cancerErik J van Helden, Lindsay Angus, C Willemien Menke-van der Houven van Oordt, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 6, 2014
89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatmentSjoukje F Oosting, Adrienne H Brouwers, Suzanne C van Es, et al.European Journal of Nuclear Medicine and Molecular Imaging|June 8, 2019
Lesion detection by [89Zr]Zr-DFO-girentuximab and [18F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinomaSarah R Verhoeff, Suzanne C van Es, Eline Boon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 2022
[89Zr]Zr-DFO-girentuximab and [18F]FDG PET/CT to Predict Watchful Waiting Duration in Patients with Metastatic Clear-cell Renal Cell CarcinomaSarah R Verhoeff, Sjoukje F Oosting, Sjoerd G Elias, et al.Pageof 1